Type: cell_therapy
Status: Promising Results
Developer: Vertex Pharmaceuticals
VX-880 uses allogeneic stem cell-derived islet cells infused into the hepatic portal vein. Updated Phase I/II data (2025-2026) shows multiple patients achieving sustained insulin independence beyond 2 years with full glycemic control. Day 90+ data: C-peptide levels restored to near-normal, HbA1c < 7.0% without exogenous insulin.
Fully differentiated iPSC-derived pancreatic islet cells replace destroyed beta cells via hepatic portal vein infusion. Patients require immunosuppression. Cells engraft in the liver and produce endogenous insulin in response to glucose.
Year: 2025-2026